Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies.
This translational pilot research is based on preliminary results using animal models. The investigators will collect samples of blood, urine and feces from up to 50 participants with well documented acute porphyrias, at 2 expert sites that are members of the Porphyrias Consortium. Collection and analysis of these samples will be used to assess feasibility of performing such studies in humans with acute porphyrias, recognizing that these disorders are more heterogeneous than reproduced in animal models, and affect individuals who cannot all be studied simultaneously and in large groups. Therefore, we will assess the feasibility of methods for collecting, processing, storing and shipping samples at multiple study sites for later biomarker analysis. Larger and more definitive studies of biomarkers will be designed and implemented based on data and experience from this pilot-feasibility study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Asymptomatic | Group 1 will have had no symptoms of porphyria in the past year. | ||
| Symptomatic and treated with hemin | Group 2 will have a history of symptoms within the past year. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hemin | Drug | Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Potential biomarkers Biomarkers | Expression of heme biosynthetic and heat and stress response genes | 10 days |
Not provided
Not provided
Inclusion Criteria:
Documented diagnosis of acute porphyria.
Exclusion Criteria:
Not provided
Not provided
Not provided
Acute intermittent porphyria, hereditary coproporphyria, variegate porphyria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karl E Anderson | University of Texas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas Medical Branch | Galveston | Texas | 77555 | United States |
Data not entered
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017118 | Porphyria, Acute Intermittent |
| D046349 | Coproporphyria, Hereditary |
| D046350 | Porphyria, Variegate |
| D011164 | Porphyrias |
| ID | Term |
|---|---|
| D017094 | Porphyrias, Hepatic |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D012873 | Skin Diseases, Genetic |
Not provided
Not provided
| ID | Term |
|---|---|
| D006427 | Hemin |
| ID | Term |
|---|---|
| D006418 | Heme |
| D008665 | Metalloporphyrins |
| D011166 | Porphyrins |
| D045725 | Tetrapyrroles |
| D011758 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |